News

The company has reported a net income of $211.61m, or $2.64 per diluted share, compared to $100.33m, or $1.35 per diluted share, for the same period last year.

MP0112 is a phase II proprietary therapeutic DARPin protein targeting VEGF under experiment for the treatment of retinal diseases. Under the pact, Molecular Partners and Allergan will jointly

Selexys Pharmaceuticals will recruit around 30 healthy subjects in the trial. The study will investigate the safety and pharmacology of SelG1 prior to advancement into a Phase II

The once-daily tablet roflumilast is an orally administered phosphodiesterase 4 (PDE4) enzyme inhibitor. Data from four randomized placebo controlled trials have shown that roflumilast reduces exacerbations and improves

Under the agreement, both the parties will jointly work for identifying, characterizing and optimizing new treatments for malaria. The ‘Orthology Malaria’ project aims at developing drug candidates from

For the first quarter of 2011, the company has reported a net income of $351,000, or $0.02 per diluted share, compared to $711,000 or $0.05 per diluted share,

Molecular Templates has created Engineered Toxin Bodies’ (ETBs) libraries that can be rapidly screened on functionality where the target may or may not be known a priori. ETBs

Launched in 1990 as an herbal energizer capsule, 30-Plus was a key brand for Ajanta Pharmaceuticals. Dabur has identified health care as a key growth area for the

Iroko has already completed Phase II studies for all of these products. Aptuit will also make batch material to satisfy requirements for product registrations. While serving as a